![](/img/cover-not-exists.png)
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
Lisberg, A., Cummings, A., Goldman, J.W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., Wolf, B., Jones, B., Madrigal, J., Horton, J., Spiegel, M., Carroll, JVolume:
13
Language:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1016/j.jtho.2018.03.035
Date:
August, 2018
File:
PDF, 389 KB
english, 2018